Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cytosorbents Corporation CTSO

Healthcare  —  Medical Devices
4.38 0.08 1.86% as of 25 Sep
Market cap
$13.6M
P/E
0.0×
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cytosorbents Corporation (CTSO) Business Profile

Updated before January 2025

Company Overview

Cytosorbents Corporation (NASDAQ: CTSO) is a leading medical technology company specializing in blood purification therapies. Founded in 1997 and headquartered in Princeton, New Jersey, Cytosorbents has established itself as a pioneer in the field of extracorporeal blood purification. The company’s flagship product, CytoSorb®, is a first-in-class blood purification technology designed to reduce cytokine storm and other inflammatory mediators in critically ill patients. The company was co-founded by Dr. Phillip Chan, who currently serves as the Chief Executive Officer, and Dr. Christian Steiner, who plays a key role in the company’s strategic direction. Cytosorbents operates globally, with a strong presence in Europe, Asia, and the United States, and has partnerships with leading healthcare organizations and distributors worldwide.

Core Business Segments

Cytosorbents Corporation focuses on the development and commercialization of blood purification technologies. Its core business segments include:

1. Blood Purification Products

  • CytoSorb®: The company’s flagship product, CytoSorb®, is a hemoadsorption cartridge designed to remove cytokines, toxins, and other inflammatory mediators from the blood. It is primarily used in critical care settings to treat conditions such as sepsis, trauma, and acute respiratory distress syndrome (ARDS).
  • ECOS-300CY®: This extracorporeal cytokine adsorption system is designed for use in conjunction with extracorporeal membrane oxygenation (ECMO) machines, providing enhanced blood purification capabilities.

2. Adjunctive Therapies

  • HemoDefend™: A blood purification technology aimed at improving the safety and quality of blood transfusions by removing contaminants such as free hemoglobin and inflammatory mediators.
  • VetResQ™: A veterinary blood purification product designed for use in animals suffering from sepsis or other inflammatory conditions.

3. Research and Development Services

Cytosorbents also offers R&D services to pharmaceutical and biotechnology companies. These services include the development of customized blood purification solutions for clinical trials and therapeutic applications.

Business Model

Cytosorbents Corporation operates on a hybrid business model that integrates product sales, licensing agreements, and research collaborations. The company generates revenue through the direct sale of its products to hospitals and healthcare providers, as well as through partnerships with distributors in international markets. Additionally, Cytosorbents licenses its technologies to third-party manufacturers and collaborates with pharmaceutical companies to develop customized blood purification solutions. The company’s focus on innovation and clinical validation ensures a steady pipeline of new products and applications, driving long-term revenue growth.

Strategic Direction

Cytosorbents is committed to expanding its global footprint and enhancing its product portfolio to address unmet medical needs. Key strategic initiatives include:

  • Geographic Expansion: The company is actively pursuing regulatory approvals in new markets, including China, Japan, and South America, to broaden its customer base.
  • Product Innovation: Cytosorbents is investing heavily in R&D to develop next-generation blood purification technologies and expand the indications for its existing products.
  • Sustainability Goals: The company is focused on reducing its environmental impact by adopting sustainable manufacturing practices and minimizing waste.
  • Strategic Partnerships: Cytosorbents continues to collaborate with leading healthcare organizations and academic institutions to advance the science of blood purification and develop new therapeutic applications.

Competitive Landscape

Cytosorbents operates in a highly competitive market, facing competition from both established medical device companies and emerging startups. Key competitors include:

  • Baxter International Inc.: A global leader in renal care and blood purification technologies.
  • Fresenius Medical Care: Known for its dialysis products and extracorporeal therapies.
  • Terumo Corporation: A Japanese medical device company specializing in blood management and cardiovascular systems.
  • ExThera Medical: A startup focused on developing blood purification devices for infectious diseases.

Despite the competition, Cytosorbents differentiates itself through its innovative technologies, strong clinical evidence, and focus on critical care applications.

Risk Factors

Cytosorbents faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its flagship product, CytoSorb®, which accounts for a significant portion of its revenue.
  • Regulatory Challenges: Obtaining and maintaining regulatory approvals in different markets can be time-consuming and costly.
  • Supply Chain Disruptions: The global supply chain crisis has the potential to disrupt the production and distribution of the company’s products.
  • Competition: The entry of new competitors and the development of alternative therapies could erode Cytosorbents’ market share.
  • Economic Uncertainty: Fluctuations in healthcare budgets and economic conditions could impact the adoption of the company’s products.

Recent Developments

Cytosorbents has made significant strides in recent years, including:

  • FDA Emergency Use Authorization: CytoSorb® received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 patients experiencing cytokine storm.
  • New Product Launches: The company introduced HemoDefend-BGA™, a next-generation blood purification cartridge designed for use in blood banks.
  • Strategic Partnerships: Cytosorbents entered into a collaboration with a leading pharmaceutical company to develop a customized blood purification solution for oncology applications.
  • Clinical Trials: The company is conducting multiple clinical trials to expand the indications for CytoSorb® and validate its efficacy in new therapeutic areas.

Investment Considerations

Strengths

  • Innovative Technology: Cytosorbents is a leader in blood purification, with a strong intellectual property portfolio and a proven track record of innovation.
  • Growing Market: The global market for blood purification therapies is expected to grow significantly, driven by rising healthcare needs and an aging population.
  • Strong Clinical Evidence: The company’s products are backed by robust clinical data, enhancing their credibility and adoption.
  • Global Presence: Cytosorbents has a well-established distribution network and a growing presence in key international markets.

Risks

  • High Dependence on CytoSorb®: The company’s financial performance is heavily reliant on the success of its flagship product.
  • Regulatory and Competitive Risks: Challenges in obtaining regulatory approvals and increasing competition could impact growth.
  • Financial Performance: Cytosorbents has yet to achieve consistent profitability, which may deter some investors.

Conclusion

Cytosorbents Corporation is a pioneering medical technology company with a strong focus on blood purification therapies. Its innovative products, global presence, and commitment to R&D position it as a leader in the field. While the company faces challenges such as regulatory hurdles and market dependence, its growth prospects remain strong, driven by expanding indications for its products and increasing global demand for critical care solutions. For investors, Cytosorbents offers a compelling opportunity to participate in the growth of a high-impact healthcare technology company.